Cisco the Newest Paris 2024 Partner - Sponsor Spotlight
aroundtherings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aroundtherings.com Daily Mail and Mail on Sunday newspapers.
Safer at Home Has a Different Meaning for This Woman With Diabetes | Health & Wellness
chathamstartribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chathamstartribune.com Daily Mail and Mail on Sunday newspapers.
Safer at Home Has a Different Meaning for This Woman With Diabetes | Health & Wellness
averyjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from averyjournal.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
INDIANAPOLIS, April 11, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo
® (selpercatinib) demonstrated encouraging antitumor activity and safety across
RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. We are excited to broaden the body of evidence for Retevmo in
RET fusion-positive cancers beyond lung and thyroid tumors, said David Hyman, M.D., chief medical officer, oncology at Lilly. These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that